Acute Coronary Syndromes 2015
Acute Coronary Syndromes 2015
Acute Coronary Syndromes 2015
Syndromes
N60B
Spring 2015
1
Case Scenario
A 55-year-old man presents with a chief complaint
of severe (10 out of 10) substernal chest pain. He
has pain radiating down his left arm and up into his
jaw, nausea, and a profound sense of impending
doom. He is covered with small beads of sweat.
Vital signs: TEMP = 37.2C; HR = 110 bpm;
BP = 150/100 mm Hg; RESP = 12
Describe your immediate assessment.
Describe your immediate general treatment.
2
Oxygen at 4 L/min
Aspirin 160 to 325 mg
Nitroglycerin SL or spray
Morphine IV (if pain not relieved
with nitroglycerin)
Oxygen Used in
Acute Coronary Syndromes
Why?
Increases supply of oxygen to ischemic tissue
When?
Always when AMI is suspected
How?
Start with nasal cannula at 2-4 L/min
maintain O2 sat greater than 90%
Remember: oxygen-IV-monitor
Watch Out!
Rarely COPD patients with hypoxic
ventilatory drive will hypoventilate
5
Nitroglycerin: Actions
Decreases pain of ischemia
Increases venous dilation
Decreases venous blood return to heart
Decreases preload and cardiac
oxygen consumption
Dilates coronary arteries
Increases cardiac collateral flow
Nitroglycerin: Indications
Class I: First 24 to 48 hours in patients with
ST-segment elevation or depression including
Nitroglycerin: Dose
Sublingual: 0.3 to 0.4 mg; repeat every 5 minutes
Spray inhaler: 2 metered doses at 5-minute intervals
IV infusion: 12.5 to 25 g bolus, 10 to 20 g/min
infusion, titrated
Nitroglycerin: Precautions
Use extreme caution if systolic BP <90 mm Hg
Use extreme caution in RV infarction
Suspect RV infarction with inferior ST changes
Limit BP drop to 10% if patient is normotensive
Limit BP drop to 30% if patient is hypertensive
Watch for headache, drop in BP, syncope,
tachycardia
Tell patient to sit or lie down during administration
9
Morphine Sulfate:
Actions, Indications
Why? (Actions)
To reduce pain of ischemia
To reduce anxiety
To reduce extension of ischemia by reducing
O2 demands
When? (Indications)
Continuing pain
Evidence of vascular congestion (acute
pulmonary edema)
Systolic blood pressure >90 mm Hg
No hypovolemia
10
Morphine Sulfate:
Dose, Precautions
How? (Dose)
2 to 4 mg titrated to effect
Goal: Eliminate pain
Watch out for (Precautions)
Drop in blood pressure, especially in patients with
Volume depletion
RV infarction
Depression of ventilation
Nausea and vomiting (common)
Bradycardia
Itching and bronchospasm (uncommon)
11
Aspirin: Actions
Why? (Actions)
Blocks formation of thromboxane A2
(thromboxane A2 causes platelets to aggregate
and arteries to constrict)
These actions will reduce
Overall mortality from AMI
Nonfatal reinfarction
Nonfatal stroke
12
Aspirin:
Indications, Dose, Precautions
When? (Indications) As soon as possible!
Standard therapy for all patients with new pain suggestive
of AMI
Give within minutes of arrival
How? (Dose) 160- to 325-mg tablet taken as soon as possible
Watch Out! (Precautions)
Relatively contraindicated in patients with active peptic
ulcer disease or asthma
Contraindicated in patients with known aspirin
hypersensitivity
Bleeding disorders
Severe hepatic disease
13
-Blockers
Mechanism of action
Blocks catecholamines from binding to
-adrenergic receptors
Reduces HR, BP, myocardial contractility
Decreases AV nodal conduction
Decreases incidence of primary VF
14
-Blockers
Absolute
Contraindications
Severe CHF/PE
SBP <100 mm Hg
Acute asthma
(bronchospasm)
2nd- or 3rd-degree
AV block
Cautions
Mild/moderate CHF
HR <60 bpm
History of asthma
Type 1 Diabetes
15
Heparin
Mechanism of action
Indirect thrombin inhibitor
Indications
PTCA or CABG
With fibrin-specific lytics
High risk for systemic emboli
Conditions with high risk for systemic
emboli, such as large anterior MI, atrial
fibrillation, or LV thrombus
16
ACE Inhibitors
Mechanism of action
Reduces BP by inhibiting angiotensin-converting
enzyme (ACE)
Alters post-AMI LV remodeling by inhibiting
tissue ACE
Lowers peripheral vascular resistance
by vasodilatation
Reduces mortality and CHF from AMI
17
Fibrinolytic Therapy
Breaks up the fibrin network that binds clots together
Indications: ST elevation >1 mm in 2 or more
contiguous leads or new LBBB or new BBB that
obscures ST
Time of symptom onset must be <6 hours
Caution: fibrinolytics can cause death from brain
hemorrhage
Agents differ in their mechanism of action, ease of
preparation and cost
1 agent currently available: alteplase (tPA, Activase)
18
Antiplatelet Agents
Blocks glycoprotein IIb/IIIa receptors on platelets
Blocked receptors cannot attach to fibrinogen
Fibrinogen cannot aggregate platelets to platelets
Indications: ACS with NO ST-segment elevation:
NonQ-wave MI
Unstable angina managed medically
UA undergoing PCI
Examples: abciximab (ReoPro), eptifibitide (Integrilin),
tirofiban (Aggrastat)
19
2. PTCA + stent
placement
1. PTCA:
Percutaneous
Transluminal
Coronary Angioplasty
3. Atherectomy:
grinds away
the plaque
20
Prognosis After MI
38% of women die within first year
Compared to 25% of men
35% of women will have second MI within 6
years
Compared to 18% of men
22
Stress
24
WISE Study
25